Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569823 | 0.85 | ALDH1A1 (0.50) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL21504136 | 0.84 | DDB1 (0.47) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL21504135 | 0.80 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL2542693 | 0.79 | DDB1 (0.54) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL23594186 | 0.78 | ALDH1A1 (0.44) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2805409 | 0.78 | DDB1 (0.52) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL31613300 | 0.78 | CYP17A1 (0.63) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL12027689 | 0.78 | ALDH1A1 (0.55) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL3933970 | 0.78 | DDB1 (0.52) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL32674110 | 0.78 | ALDH1A1 (0.50) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-118638043-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118059104-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-115175901-B | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230113609-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4069702-A1 | SSTR5 ANTAGONISTS | Kallyope, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115175901-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021113368-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113368-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | ALDH1A1 1033/4885DDB1 2540/4885CRBN 151/4885 |
| US-20230113609-A1 | SSTR5 ANTAGONISTS | SSTR5, GLP1R, GPR119 | ALDH1A1 2825/4885DDB1 4119/4885CRBN 4203/4885 |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | ALDH1A1 442/4885DDB1 1355/4885CRBN 257/4885 |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | ALDH1A1 442/4885DDB1 1355/4885CRBN 257/4885 |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | ALDH1A1 442/4885DDB1 1355/4885CRBN 257/4885 |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | ALDH1A1 442/4885DDB1 1355/4885CRBN 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.